• Publications

Publications by founders

Immunoregulatory antigens - novel targets for cancer immunotherapy
Chinese Clinical Oncology, March 2018

The Balance Players of the Adaptive Immune System
Cancer Research, February 2018

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy
OncoImmunology, August 2017

CCL22 specific T Cells: Modulating the immunosuppressive tumor microenvironment
OncoImmunology, September 2016

Anti-regulatory T cells 
Semin Immunopathology, September 2016

Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab
Cytotherapy, August 2016

PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine
Oncoimmunology, July 2016

PD-L1-specific T cells
Cancer Immunol Immunotherapy, January 2016

Novel understanding of self-reactive T cells
Oncoimmunology, August 2015

Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
Journal of the National Cancer Institute, June 2015

Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase
Clinical Cancer Research. January 2014

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
Leukemia, January 2014

HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients
Cancer Research, March 2013

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
Blood, February 2011